Alcon Enters Nasal Market With Approval Of Seasonal Allergic Rhinitis Spray
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss eye care company wins FDA approval of Patanase after withdrawal and resubmission of NDA.
You may also be interested in...
Novartis To Acquire Majority Stake In Alcon
Deal offers synergies with firm’s Ciba Vision affiliate and ex-U.S. marketing rights to Lucentis.
Alcon Could Re-File Patanase Nasal Spray NDA By End Of 2007
Olopatadine reformulation will require additional preclinical testing, firm says.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.